Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

Financials ($)
Sales 2017 88,6 M
EBIT 2017 12,2 M
Net income 2017 -0,72 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 128 M
EBIT 2018 27,0 M
Net income 2018 12,0 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 46,50
EV / Sales2017 6,40x
EV / Sales2018 4,42x
Capitalization 495 M
More Financials
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
07/27Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
05/26 TELIGENT : Commerce Bank Has $145,000 Stake in Teligent Inc
05/24 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Submission of Matters to a Vote of S..
05/24 TELIGENT, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/16 TELIGENT, INC. : To Present At Bank Of America Merrill Lynch Healthcare Conferen..
05/10 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Results of Operations and Financial ..
05/10 TELIGENT : Results of Operations and Financial Condition, Financial Statements a..
05/10 TELIGENT : Management's Discussion and Analysis of Financial Condition and Resul..
05/03 TELIGENT, INC. : To Present At Deutsche Bank 42nd Annual Health Care Conference ..
05/03 TELIGENT : tops 1Q profit forecasts
05/02 TELIGENT, INC. : Results of Operations and Financial Condition, Financial Statem..
More news
Sector news : Pharmaceuticals - NEC
09:22a COVESTRO : vows to cash out to shareholders if no takeover on cards
04:55a MYLAN : Investors call on Mylan chairman, director to step down
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75 $
Spread / Average Target 4,8%
Consensus details
EPS Revisions
More Estimates Revisions
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON17.19%360 489
ROCHE HOLDING LTD.8.34%226 454
NOVARTIS11.74%223 476
PFIZER3.91%200 985
MERCK AND COMPANY10.68%178 223
More Results